PB-718 vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
PB-718
Developed by PegBio
NCT06147544 · Phase 1/2 · completed
The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
Reported efficacy
Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)
Result source: NCT06066515
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PB-718 | survodutide |
|---|---|---|
| Body weight, % change | —Not reported | -14.9% vs -2.8%−12.1 vs placeboNCT046673774 other results
|
| Weight loss of 5% or more | —Not reported | 82.8% vs 25.9%+56.9 vs placeboNCT046673773 other results
|
| Weight loss of 10% or more | —Not reported | 68.8% vs 11.1%+57.7 vs placeboNCT046673773 other results
|
| Waist circumference, change (cm) | —Not reported | -16.0 vs -4.0−12 vs placeboNCT046673773 other results
|
Body weight, % change
- PB-718
- —Not reported
- survodutide
- -14.9% vs -2.8%−12.1 vs placeboNCT04667377
4 other results
- -13.2% vs -2.8% NCT04667377
- -12.5% vs -2.8% NCT04667377
- -6.2% vs -2.8% NCT04667377
- -16.6% vs -3.2% NCT06066515
Weight loss of 5% or more
- PB-718
- —Not reported
- survodutide
- 82.8% vs 25.9%+56.9 vs placeboNCT04667377
3 other results
- 82% vs 25.9% NCT04667377
- 81% vs 25.9% NCT04667377
- 60.7% vs 25.9% NCT04667377
Weight loss of 10% or more
- PB-718
- —Not reported
- survodutide
- 68.8% vs 11.1%+57.7 vs placeboNCT04667377
3 other results
- 65.6% vs 11.1% NCT04667377
- 65.5% vs 11.1% NCT04667377
- 33.9% vs 11.1% NCT04667377
Waist circumference, change (cm)
- PB-718
- —Not reported
- survodutide
- -16.0 vs -4.0−12 vs placeboNCT04667377
3 other results
- -15.0 vs -4.0 NCT04667377
- -15.0 vs -4.0 NCT04667377
- -8.3 vs -4.0 NCT04667377
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PB-718: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. PB-718: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | survodutide |
|---|---|
| Dropout rate | —4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results28.6%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.4%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 29.5%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results23.4%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 18.2%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 14.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 16.7%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.4%4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results—4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence 5.6%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 3.3%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 2.2%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 4.8 mga nausea 59.3% (placebo 19.5%) constipation 24.1% (placebo 5.2%) vomiting 24.1% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence show 3 more results3.6 mg nausea 63.4% (placebo 19.5%) vomiting 39.4% (placebo 5.2%) constipation 31% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 65.2% (placebo 19.5%) vomiting 30.4% (placebo 5.2%) diarrhoea 22.8% (placebo 10.4%) NCT04667377 · Phase 2 · registry result, not featured evidence 0.6 mg nausea 39.1% (placebo 19.5%) diarrhoea 23.9% (placebo 10.4%) covid-19 19.6% (placebo 22.1%) NCT04667377 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
survodutide
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PB-718's landscape · survodutide's landscape